All g-HAT articles
-
NewsStudy of simple acoziborole regime raises hope for elimination of sleeping sickness in Africa
The Drugs for Neglected Diseases initiative (DNDi) and Sanofi have announced treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigational treatment for sleeping sickness.